Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.17 -0.33 (-0.21%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
Verizon, Walgreens, 3M: 3 high-yield Dow stocks to buy now?
Dow's high-yielding trio, Verizon, Walgreens, and 3M face challenges, which are reflected in their stock-price declines. 
Via MarketBeat
Topics Stocks
Exposures US Equities
2 Healthcare Dividend Kings to Buy and Hold Forever
It's going to take a lot to interrupt these companies' streaks. 
Via The Motley Fool
7 Dividend Stocks That Pay Me More Than $500 Per Month
These stocks pay safe, reliable, and growing dividends. 
Via The Motley Fool
Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
From Johnson & Johnson
Via Business Wire
3 High Yield Dividend Aristocrats To Buy Now
The Dividend Aristocrats have increased their dividends every year for at least 25 years in a row. 
Via Talk Markets
Analyzing NYSE:JNJ's Dividend Potential.
Is JOHNSON & JOHNSON (NYSE:JNJ) a Good Fit for Dividend Investing? 
Via Chartmill
The Analyst Verdict: Johnson & Johnson In The Eyes Of 12 Experts
Via Benzinga
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000
FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address... 
Via Benzinga
Exposures Product Safety
The 7 Best Blue-Chip Stocks to Invest In for Big Gains in 2024
Investors looking for reliable stocks that can be expected to continuously rise and provide strong returns should consider these names. 
Via InvestorPlace
4 med tech stocks with improving prognosis for 2024
MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025. 
Via MarketBeat
Exposures COVID-19
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding. 
Via InvestorPlace
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
Will Novo Nordisk Be a $1 Trillion Company by 2030?
Novo Nordisk's market cap has ballooned thanks to the overwhelming success of its Ozempic, Wegovy, and Rybelsus medications. 
Via The Motley Fool
Wall Street's Greatest Dividend Stock Just Made History Again, and 99% of Investors Probably Don't Realize It Exists
This virtually unknown company has been paying a consecutive dividend to its investors for more than 200 years. 
Via The Motley Fool
3 Perfect Stocks for Retirees to Buy Hand Over Fist in the New Bull Market
These industry-leading, time-tested companies are ideal for retired investors. 
Via The Motley Fool
Hedge Fund Favorites: 7 Stocks the Big Money Is Loving Now
Team up with the schoolyard bully so to speak with these compelling ideas for hedge fund favorite stocks to buy. 
Via InvestorPlace
Johnson & Johnson To Pay $149M In Opioid Settlement, Washington State AG Says 'We Are Not Done'
J&J settles opioid lawsuit with Washington state for $149.5 million in one lump sum, giving more resources to fight the fentanyl crisis. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson
These companies have been focusing on growing their operations, but which stock is likely to provide investors with better returns? 
Via The Motley Fool
Should You Buy the Dogs of the Dow in 2024?
The popular dividend-investing strategy has been around for years. Is it right for you? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Dividend Dynamos- 7 Stocks Delivering Consistent Cash Flow This Year
Investing in dividend stocks with consistent cash flow will help build a portfolio that generates passive income throughout 2024. 
Via InvestorPlace
Stock Market Continues To Rally; ASML, Netflix, Tesla, Intel Are Big Earnings Movers: Weekly Review
The S&P 500 and Dow Jones hit fresh record highs on Friday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, Jan. 26
Looking for a break of {b} of 2 to enter long. 
Via Talk Markets
Abbott Laboratories on track for new highs in 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact. 
Via MarketBeat
Exposures COVID-19
Better Dividend Stock to Buy Now: Johnson & Johnson vs. Verizon
Both recently reported results from the fourth quarter of 2023 and their performances could hardly look more different. 
Via The Motley Fool
Intuitive Surgical’s post-earnings dip is a healthy time to buy
Intuitive Surgical had a solid quarter, but strength was expected, and the stock sold off; a healthy correction is good, but will investors buy the dip? 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
7 Dividend Stocks to Buy and Never Sell: January 2024 Edition
Seeking out dividend stocks to buy and hold is a time-tested strategy that has proved itself in all types of markets 
Via InvestorPlace
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list. 
Via Benzinga
Exposures Product Safety
What's Going On Johnson & Johnson Stock Today?
JNJ reports strong earnings, beats expectations for Q4 of 2023, with increased sales and successful acquisitions. Stock closes lower, settles talc litigation, and delays competitor's launch. 
Via Benzinga
Topics Earnings
Exposures Financial
Nasdaq, S&P 500 Futures Jump As Wall Street Eagerly Awaits Tesla's Q4 Earnings: Analyst Says Rally Broadening But Favors These Stocks
Earnings have served to mitigate early January's weakness, and sentiment appears to be upbeat going into Wednesday's session. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.